Study for moderate alcoholic hepatitis after heavy drinking
Treatments studied
Part of Digestive system clinical trials.
This early-phase study is testing a treatment approach for people with alcoholic hepatitis (liver inflammation caused by heavy alcohol use). It may help by improving liver function and outcomes in people who meet specific lab and health criteria.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’ve been diagnosed with alcoholic hepatitis (confirmed by clinician findings, lab results, or a liver biopsy)
- You generally drink heavily: for at least 6 months (about >60 g/day for men or >40 g/day for women)
- Your MELD score is under 21, and your bilirubin is above 3 mg/dL
- Your liver enzyme tests fit the study pattern (including AST above 50 and AST/ALT ratio above 1.5; both AST and ALT under 400)
- You are not pregnant or breastfeeding
- You do not have certain complications (like recent GI bleeding, active infection, brain confusion from liver disease, kidney failure/dialysis, or a current alcohol withdrawal situation)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how immune cells in the blood respond in people with alcoholic hepatitis and in people who drink heavily (with no known liver disease). It may help researchers understand why liver inflammation happens after heavy alcohol use.
This trial tests a new medicine called MRG-001 for people with severe alcoholic hepatitis, a liver condition caused by heavy drinking. The study aims to see if the drug can help improve liver function and reduce symptoms.
This trial tests whether giving corticosteroids for a longer time, or adding a medicine called N-acetylcysteine, can help people with severe alcoholic hepatitis. It is for patients who have been drinking heavily and recently developed jaundice.
This trial tests an experimental drug for people with severe alcoholic hepatitis that did not improve with steroids. Participants should have a moderate level of organ failure, but not require a breathing tube or kidney dialysis.
This trial compares two treatments for alcoholic hepatitis: a medicine called mycophenolate mofetil versus the standard steroid treatment. The goal is to see which one works better and has fewer side effects for patients with this liver condition.
This early-phase study tests HA35 in people who currently drink less alcohol than typical weekly drinking limits. It aims to see whether the supplement is safe and whether it affects the body in people who are not heavy drinkers.
Hear when a new Alcoholic Hepatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.